AllianceBernstein
KNSA icon

AllianceBernstein’s Kiniksa Pharmaceuticals KNSA Stock Holding History

AllianceBernstein’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.7M Buy
598,888
+270,614
+82% +$12M 0.01% 830
2025
Q4 		$13.5M Buy
+328,274
New +$13.2M ﹤0.01% 1117
2025
Q2 		– Sell
-39,560
Closed -$879K – 3278
2025
Q1 		$879K Hold
39,560
– – ﹤0.01% 2304
2024
Q4 		$782K Hold
39,560
– – ﹤0.01% 2439
2024
Q3 		$989K Buy
+39,560
New +$964K ﹤0.01% 2336
2024
Q2 		– Sell
-39,560
Closed -$781K – 3268
2024
Q1 		$781K Hold
39,560
– – ﹤0.01% 2392
2023
Q4 		$694K Sell
39,560
-2,340
-6% -$38.5K ﹤0.01% 2448
2023
Q3 		$728K Hold
41,900
– – ﹤0.01% 2381
2023
Q2 		$590K Hold
41,900
– – ﹤0.01% 2546
2023
Q1 		$451K Hold
41,900
– – ﹤0.01% 2614
2022
Q4 		$628K Hold
41,900
– – ﹤0.01% 2511
2022
Q3 		$538K Buy
41,900
+5,700
+16% +$64.9K ﹤0.01% 2611
2022
Q2 		$351K Buy
36,200
+6,200
+21% +$57.9K ﹤0.01% 2827
2022
Q1 		$298K Buy
30,000
+100
+0.3% +$1.06K ﹤0.01% 2873
2021
Q4 		$352K Buy
29,900
+1,000
+3% +$12.3K ﹤0.01% 2892
2021
Q3 		$329K Sell
28,900
-3,700
-11% -$48.2K ﹤0.01% 2928
2021
Q2 		$454K Buy
32,600
+10,600
+48% +$161K ﹤0.01% 2850
2021
Q1 		$407K Sell
22,000
-7,700
-26% -$157K ﹤0.01% 2762
2020
Q4 		$525K Buy
29,700
+1,400
+5% +$24.6K ﹤0.01% 2565
2020
Q3 		$434K Sell
28,300
-1,200
-4% -$22.5K ﹤0.01% 2595
2020
Q2 		$752K Buy
29,500
+3,600
+14% +$75.2K ﹤0.01% 2359
2020
Q1 		$401K Buy
25,900
+6,700
+35% +$105K ﹤0.01% 2464
2019
Q4 		$212K Hold
19,200
– – ﹤0.01% 2902
2019
Q3 		$163K Buy
19,200
+5,300
+38% +$58.6K ﹤0.01% 2989
2019
Q2 		$188K Buy
+13,900
New +$216K ﹤0.01% 2984
2019
Q1 		– Sell
-8,800
Closed -$247K – 3131
2018
Q4 		$247K Buy
+8,800
New +$184K ﹤0.01% 2811

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

AllianceBernstein's KNSA Position: Q1 2026 in Review

AllianceBernstein increased its Kiniksa Pharmaceuticals (KNSA) stake by 82% in Q1 2026, buying an estimated $12M and bringing the position to 598,888 shares worth $24.7M. The position accounts for 0.01% of the portfolio, ranked #830.

AllianceBernstein first reported a position in KNSA in Q4 2018 and has held it in 26 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • AllianceBernstein held 598,888 shares of Kiniksa Pharmaceuticals worth $24.7M as of Q1 2026.
  • AllianceBernstein bought 270,614 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $12M.
  • Kiniksa Pharmaceuticals made up 0.01% of AllianceBernstein's portfolio in Q1 2026, its #830 holding.
  • AllianceBernstein first reported a position in Kiniksa Pharmaceuticals in Q4 2018 and has held it in 26 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.